Literature DB >> 9450229

HIV dementia and the basal ganglia.

J R Berger1, A Nath.   

Abstract

Infection with the human immunodeficiency virus frequently results in a dementing illness which manifests predominantly as a subcortical dementia. Parkinsonian features may be prominent in these patients and may on occasion be the presenting manifestation. These patients are exquisitely sensitive to dopaminergic blocking agents. Radiological studies, metabolic uptake studies and pathological examination of the brain suggest that the basal ganglia are the major target of this infection. Although further studies are necessary to determine appropriate treatment for this condition and to develop an understanding of the underlying pathophysiological mechanisms, available evidence suggests that the response to dopamine agonists may be variable and that viral strains and viral products may specifically target cells within the basal ganglia.

Entities:  

Mesh:

Year:  1997        PMID: 9450229     DOI: 10.1159/000150539

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  59 in total

1.  Acceleration of HIV dementia with methamphetamine and cocaine.

Authors:  A Nath; W F Maragos; M J Avison; F A Schmitt; J R Berger
Journal:  J Neurovirol       Date:  2001-02       Impact factor: 2.643

2.  Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses.

Authors:  C Scheller; G Arendt; T Nolting; C Antke; S Sopper; M Maschke; M Obermann; A Angerer; I W Husstedt; F Meisner; E Neuen-Jacob; H W Müller; P Carey; V Ter Meulen; P Riederer; E Koutsilieri
Journal:  J Neural Transm (Vienna)       Date:  2010-05-09       Impact factor: 3.575

3.  Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy.

Authors:  Alan Winston; Chris Duncombe; Patrick C K Li; John M Gill; Stephen J Kerr; Rebekah L Puls; Simon D Taylor-Robinson; Sean Emery; David A Cooper
Journal:  Neuroradiology       Date:  2012-07-07       Impact factor: 2.804

4.  Differential involvement of p38 and JNK MAP kinases in HIV-1 Tat and gp120-induced apoptosis and neurite degeneration in striatal neurons.

Authors:  I N Singh; N El-Hage; M E Campbell; S E Lutz; P E Knapp; A Nath; K F Hauser
Journal:  Neuroscience       Date:  2005-08-19       Impact factor: 3.590

5.  Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge.

Authors:  Landhing M Moran; Michael Y Aksenov; Rosemarie M Booze; Katy M Webb; Charles F Mactutus
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

6.  Mapping mental number line in physical space: vertical and horizontal visual number line orientation in asymptomatic individuals with HIV.

Authors:  Yelena Bogdanova; Sandy Neargarder; Alice Cronin-Golomb
Journal:  Neuropsychologia       Date:  2008-06-04       Impact factor: 3.139

Review 7.  Implementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors.

Authors:  Italo Mocchetti; Alessia Bachis; Lee A Campbell; Valeriya Avdoshina
Journal:  J Neuroimmune Pharmacol       Date:  2013-07-06       Impact factor: 4.147

8.  Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice.

Authors:  James P Kesby; David T Hubbard; Athina Markou; Svetlana Semenova
Journal:  Addict Biol       Date:  2012-12-18       Impact factor: 4.280

9.  Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction.

Authors:  L M Moran; R M Booze; K M Webb; C F Mactutus
Journal:  Exp Neurol       Date:  2012-10-11       Impact factor: 5.330

Review 10.  Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention--A Comparison with Parkinson's Disease.

Authors:  S DeVaughn; E M Müller-Oehring; B Markey; H M Brontë-Stewart; T Schulte
Journal:  Neuropsychol Rev       Date:  2015-11-17       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.